MYO — Myomo, Inc.

Myomo Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $10.1 million, a 10% increase year-over-year, driven by higher unit sales despite a lower average selling price (ASP).
• Units Shipped: 186 MyoPro units, up 16% from the previous year.
• ASP: Approximately $54,300, down 5% year-over-year but normalized for accounting changes, ASP increased by 3%.
• Gross Margin: 63.8%, a decline from 75.4% in the prior year, impacted by higher labor and material costs.
• Operating Loss: $3.5 million, compared to a $1 million loss in Q3 2024.
• Net Loss: $3.7 million, or $0.09 per share, worsening from a $1 million loss or $0.03 per share in the prior year.
• Cash Position: $12.6 million as of September 30, 2025, with a cash burn of $2.9 million in Q3.

2. Strategic Updates and Business Highlights

• International Growth: Record international revenue of $1.8 million, primarily from Germany, up 63% year-over-year.
• O&P Channel Development: Revenue from the O&P channel reached $900,000, up 154% year-over-year, indicating successful expansion efforts.
• MyoConnect Program: Launched to improve patient referrals from clinicians without incurring advertising costs, showing early traction.
• Insurance Coverage Expansion: Increased authorizations from Medicare Advantage plans and new contracts signed, covering 35 million lives.
• Operational Efficiency: Focus on reducing customer acquisition costs and managing operating expenses effectively.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Reiterated guidance of $40 million to $42 million, representing over 23% growth from the previous year.
• 2026 Focus: Plans to diversify revenue streams away from advertising-driven sales, emphasizing MyoConnect and O&P channel growth.

4. Bad News, Challenges, or Points of Concern

• Medicare Advantage Revenue Decline: Revenue from Medicare Advantage down 18% year-over-year due to high pre-authorization denials.
• Gross Margin Pressure: Significant decline in gross margin due to increased operational costs and changes in revenue recognition.
• Backlog Reduction: A decrease in backlog by 34% year-over-year, attributed to lower Medicare Advantage authorizations.
• Operating Expenses: Total operating expenses increased by 26% year-over-year, driven by higher payroll and advertising costs.

5. Notable Q&A Insights

• O&P Business Scale: Approximately 30 units shipped into the O&P channel in Q3, with plans for continued growth.
• Customer Acquisition Costs: New marketing strategies are being evaluated to improve lead generation and reduce costs.
• Pipeline Growth: The patient pipeline increased by 32% year-over-year, with expectations for continued growth through the MyoConnect program.
• Debt Financing: The recent $17.5 million term loan was taken to support growth, with management confident in the ability to repay it within 18 months.
• Breakeven Revenue Target: Estimated quarterly revenue needed to reach breakeven is now around $16 million to $17 million, down from previous estimates.

This summary encapsulates Myomo's financial performance, strategic initiatives, outlook, and challenges faced during Q3 2025, providing a balanced view of the company's current status and future direction.